Sweden's BioArctic Q4 revenue rises 82% on Leqembi royalties

BioArctic AB

18/02/2026 07:09

Overview

Swedish biopharma's Q4 net revenue rose to SEK 184 mln, driven by Leqembi royalties

Operating profit for Q4 was SEK 33.2 mln, reversing a loss from last year

Company's cash flow from operations improved significantly to SEK 313.3 mln

Outlook

BioArctic expects FDA decision on Leqembi Iqlik by end of May

Company anticipates completing Phase 2a study for exidavnemab in 2026

BioArctic sees strong interest in BrainTransporter technology

Result Drivers

LEQEMBI ROYALTIES - Q4 revenue growth driven by 31% increase in Leqembi royalties despite currency impacts

MARKET EXPANSION - Leqembi approvals in Brazil, Canada, and UK contributed to revenue growth

NEW ADMINISTRATION METHOD - Launch of Leqembi Iqlik for home use in US expected to boost sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
SEK 184 mln
Q4 Adjusted EPS
-SEK 0.10
Q4 Net Income
-SEK 8.80 mln
Q4 Adjusted Free Cash Flow
SEK 313.30 mln
Q4 Operating profit
SEK 33.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for BioArctic AB is SEK338.50, about 4.4% above its February 17 closing price of SEK324.20

The stock recently traded at 105 times the next 12-month earnings vs. a P/E of 72 three months ago

Press Release: ID:nWkr7qpbGf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)